To test the therapeutic potential of BRD4 degradation for T-ALL, we used conditional knockout mice with T cell-specific PTEN deletion in which T-ALL developed and that had activating Notch1 mutations [35]. This evidence concerns the gene BRD4 and acute lymphoblastic leukemia.